Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Contango Silver & Gold Inc. Common Stock
Talon Metals Corp
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
114.62
-1.25 (-1.07%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Incyte Bets on Drug Pipeline and Deals for Growth After Jakafi Exclusivity Ends
↗
November 20, 2026
Incyte (NASDAQ:INCY) is counting on a pipeline of cancer and immunology treatments, along with potential acquisitions, to support growth after JAKAFI loses exclusivity, executives said at the Jefferies...
Via
MarketBeat
Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch Loom
↗
November 20, 2026
Incyte (NASDAQ:INCY) is counting on growth from its existing medicines and a pipeline of late-stage treatments to support the company after JAKAFI loses exclusivity at the end of 2028, executives said...
Via
MarketBeat
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
November 16, 2026
From
Incyte
Via
Business Wire
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
↗
November 11, 2026
Incyte (NASDAQ:INCY) is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as...
Via
MarketBeat
Incyte (NASDAQ:INCY) Q3 Beat Overshadowed by Below-Consensus Sales Guidance
↗
October 29, 2026
Via
Chartmill
Discover the top S&P500 movers in Monday's after-hours session.
↗
October 12, 2026
Via
Chartmill
Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup
↗
September 30, 2026
Via
Chartmill
1 healthcare stock to research further and 2 we avoid
November 05, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via
StockStory
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
November 04, 2026
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
November 04, 2026
From
Incyte
Via
Business Wire
INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins
October 30, 2026
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on yea...
Via
StockStory
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum
↗
September 18, 2026
Via
Chartmill
S&P 500 Gap Movers for October 30, 2026
↗
October 30, 2026
Via
Chartmill
Topics
Stocks
Incyte (INCY) Q3 2026 Earnings Call Transcript
↗
October 29, 2026
Revenue grew 14% as core business surged 30%, with guidance raised on Opzelura momentum.
Via
The Motley Fool
Topics
Earnings
What Incyte (INCY) Said on Its Q3 Earnings Call
↗
October 29, 2026
Incyte (NASDAQ:INCY) reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in...
Via
MarketBeat
Topics
Earnings
Incyte’s (NASDAQ:INCY) Q3 2026 sales beat estimates but full-year sales guidance misses expectations significantly
October 29, 2026
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 14% year on year ...
Via
StockStory
Topics
Earnings
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
October 29, 2026
From
Incyte
Via
Business Wire
Incyte (INCY) reports Q3: everything you need to know ahead of earnings
October 27, 2026
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Thursday before market open. Here’s what to look for. Incyte beat a...
Via
StockStory
Topics
Artificial Intelligence
Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers
↗
October 26, 2026
Incyte (NASDAQ:INCY) presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “’890,”...
Via
MarketBeat
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
October 26, 2026
From
Incyte
Via
Business Wire
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
October 24, 2026
From
Genmab A/S
Via
Business Wire
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
October 24, 2026
From
Incyte
Via
Business Wire
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
October 18, 2026
From
Incyte
Via
Business Wire
2 High-Flying Stocks with Competitive Advantages and 1 We Question
October 16, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Via
StockStory
Incyte to Report Third Quarter Financial Results
October 08, 2026
From
Incyte
Via
Business Wire
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
September 30, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
Via
StockStory
Topics
Artificial Intelligence
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
September 25, 2026
From
Mirum Pharmaceuticals, Inc. and Incyte
Via
Business Wire
Discover the top S&P500 movers in Tuesday's pre-market session.
↗
September 22, 2026
Via
Chartmill
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
September 22, 2026
From
Incyte
Via
Business Wire
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target
↗
September 19, 2026
Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after...
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.